Euroz Hartleys Report | 28 January 2022

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.

2022 is described as “a big year ahead”.

Click here to view the report.

Quarterly Activities Report and 4C

Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2021.

Key highlights from this period include:

  • Botanix’s canine atopic dermatitis program, BTX 1204A, is progressing well. Following the launch in September last year, recruitment has been strong, and the study is on track to finish enrolment this quarter.
  • BTX 1702 Phase 1b/2a Rosacea Study continues to progress well with enrolment on target to be completed mid-year. This study is of strategic importance for the Company, as the results will provide key safety and efficacy data, as well as other valuable insights for our wider clinical development program.
  • Pre-clinical work to support the initiation of a Phase 2 human study for its BTX 1801 antimicrobial program is complete with the clinical study planned to initiate at the end of this quarter.

Botanix’s balance sheet remains strong, with $16.8 million in cash at closing of 4Q 2021 with R&D tax return to come this quarter.

Read today’s ASX release here.

New Study Finds Antimicrobial Resistance Now A Leading Cause Of Death Worldwide

A recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections. 

New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections.

According to the paper’s co-author Prof Chris Murray:

“These new data reveal the true scale of antimicrobial resistance worldwide, and are a clear signal that we must act now to combat the threat.”

Twelve months ago, Botanix published important research data in collaboration with the University of Queensland showing the ability of synthetic CBD to kill a select group of Gram-negative bacteria, and highlighting the potential of CBD as the foundation of a new class of antimicrobials.

Read the article in The Guardian

Edison Open House Video

Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the  2022 Edison Open House: Global Healthcare virtual event this week.

He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:

“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”

2022 Edison Open House: Global Healthcare

Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.

Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.

Click here to register, it’s free.

Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.

Click here to read the report.

DEAL NEWS | Pfizer enters CBD market

At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone.

Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion.

According to the official press release from Pfizer, ​​Arena holds a ‘diverse and promising’ portfolio, including an innovative CB2 agonist and dermatological disease candidate.

Read the story on

Read the official Pfizer press release